Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.

Journal of thoracic imaging - 1 Mar 2023

Nishino Mizuki, Lu Junwei, Hino Takuya, Vokes Natalie I, Jänne Pasi A, Hatabu Hiroto, Johnson Bruce E

Abstract excerpt

PURPOSE: In patients with advanced non-small cell lung cancer (NSCLC) and oncogenic driver mutations treated with effective targeted therapy, a characteristic pattern of tumor volume dynamics with an initial regression, nadir, and subsequent regrowth is observed on serial computed tomography (CT) scans. We developed and validated a linear model to predict the tumor volume nadir in EGFR -mutant advanced NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tumor Burden

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34524205
DOI: 10.1097/RTI.0000000000000615
PMCID: PMC8920948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.PMID 34524205Read ↗

Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.Semantic proximity Read ↗

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Semantic proximity Read ↗

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.Semantic proximity Read ↗

Prediction Models of Tumor Growth Trajectories Based on Pretreatment CT Images of TKI-Treated Lung Cancer PatientsSemantic proximity Read ↗

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.Semantic proximity Read ↗

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Mathematical models of tumor volume dynamics in response to radiotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.